Drugs / TQA3038
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06085053 | Nov 2023 → Dec 2024 | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06452693 | Jun 2024 → Sep 2026 overdue | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQA3038 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06452693 ↗ |
| Route | Subcutaneous | “administered subcutaneously (SC).” NCT06085053 ↗ |